Myomo, Inc. (MYO)

Myomo's stock price has experienced significant volatility and a general decline over the past six months. Key events impacting the stock include the Q3 2025, Q4 2025, and Q1 2026 earnings releases, analyst price target adjustments, and stock price movement. The stock has seen a decline of 74.06% from May 8, 2025, to May 7, 2026. However, it moved above its 50-day moving average on April 14, 2026, and the 10-day moving average crossed bullishly above the 50-day moving average on April 17, 2026, indicating a potential shift to an upward trend.

Myomo, Inc. has historically experienced seasonal patterns in its revenue. The fourth quarter of 2025 was Myomo's strongest revenue quarter of that year, with $11.4 million in revenue. This suggests that demand may be stronger in the latter part of the year, potentially influenced by factors such as insurance benefits resets or patient decision-making cycles.

Myomo, Inc. specializes in wearable medical robotics, focusing on myoelectric orthotics for individuals with neuromuscular disorders and upper-limb paralysis. Their core product, the MyoPro, is a powered upper-limb orthosis that restores function to weakened or paralyzed arms by sensing EMG signals. The company has also introduced the MyoPro 2x, MyoCare, MyoPal, and MyoCoach. Myomo's products are designed for adults and adolescents suffering from conditions like CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, and other neurological disorders.

Myomo, Inc. has a global presence, delivering its MyoPro devices in the U.S. and Canada. The company has established a footprint in Europe, with operations managed from Germany. They also have O&P distribution partners in Europe and Australia and have pursued expansion into China through a joint venture with Ryzur Medical. The company's headquarters are located in Burlington, Massachusetts, with sales and clinical professionals across the U.S.

Myomo's brand reputation is closely tied to the clinical effectiveness and reimbursement of its MyoPro device. The company has faced challenges including reimbursement struggles, advertising effectiveness issues, anemic O&P market uptake, and pipeline attrition. Despite these challenges, Myomo announced the availability of MyoPro at Ottobock Care Clinics in the U.S. in May 2026 and launched the Myomo Mobile App in April 2026.

Myomo, Inc. ownership is a mix of institutional, retail, and individual investors. Approximately 13.00% of the company's stock is owned by Institutional Investors. Insiders own approximately 7.83% of the stock. Paul R. Gudonis is noted as the largest individual Myomo shareholder, owning 1.26 million shares, representing 3.27% of the company.